A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Status:
Recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA
vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and
mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.